AgomAb Therapeutics(AGMB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AGMB AgomAb Therapeutics

交易中 10-12 14:23:23 EDT

9.25

+0.17

+1.87%

最高9.64	最低9.08	成交量3.79万
今开9.08	昨收9.08	日振幅6.17%
总市值4.56亿	流通市值1.28亿	总股本4,925万
成交额35.18万	换手率0.27%	流通股本1,384万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AGMB","market":"US","secType":"STK","nameCN":"AgomAb Therapeutics","latestPrice":9.25,"timestamp":1791829391598,"preClose":9.08,"halted":0,"volume":37892,"delay":0,"changeRate":0.018722466960352416,"floatShares":13836000,"shares":49248000,"eps":-4.51426,"marketStatus":"交易中","change":0.17,"latestTime":"10-12 14:23:23 EDT","open":9.08,"high":9.64,"low":9.08,"amount":351751.284432,"amplitude":0.061674,"askPrice":9.29,"askSize":142,"bidPrice":9.25,"bidSize":352,"shortable":3,"etf":0,"ttmEps":-4.51426,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1791835200000},"marketStatusCode":2,"adr":0,"adrRate":1,"listingDate":1770354000000,"exchange":"NASDAQ","adjPreClose":9.08,"postHourTrading":{"tag":"盘后","latestPrice":9.26,"preClose":9.08,"latestTime":"19:47 EDT","volume":4564,"amount":41610.46,"timestamp":1791589634388,"change":0.18,"changeRate":0.019824,"amplitude":0.019824},"volumeRatio":0.377275},"requestUrl":"/m/hq/s/AGMB/tweets","defaultTab":"tweets","newsList":[{"id":"1108737836","title":"Agomab Therapeutics：AGMB-447在IPF患者中展示出4.5毫克Bid剂量下的优越安全性与耐受性","url":"https://stock-news.laohu8.com/highlight/detail?id=1108737836","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108737836?lang=zh_cn&edition=full","pubTime":"2026-09-15 04:13","pubTimestamp":1789416788,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics公司今日宣布，其候选药物AGMB-447在特发性肺纤维化（IPF）患者中展现出令人鼓舞的安全性和耐受性数据。该项研究聚焦于4.5毫克每日两次（Bid）的给药方案，初步结果令人振奋。\n数据表明，该剂量水平下的药物耐受性表现良好，患者未出现预期之外的不良事件。这一发现为AGMB-447的后续临床开发奠定了坚实基础。\n作为一家专注于纤维化疾病治疗领域的生物制药企业，Agomab Therapeutics正积极推进该候选药物的临床研究进程。此次公布的结果进一步验证了公司在纤维化治疗管线上的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108518383","title":"Agomab公布Agmb-447特发性肺纤维化1期积极结果及2期Inspiria研究设计","url":"https://stock-news.laohu8.com/highlight/detail?id=1108518383","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108518383?lang=zh_cn&edition=full","pubTime":"2026-09-15 04:06","pubTimestamp":1789416373,"startTime":"0","endTime":"0","summary":"Agomab近日对外宣布，其针对特发性肺纤维化患者所研发的在研药物Agmb-447，在1期临床试验中取得了令人振奋的积极数据。与此同时，该公司还正式揭晓了即将启动的2期临床研究——Inspiria研究的设计方案。关于2期Inspiria研究的规划，Agomab表示将基于1期所确立的给药方案与剂量范围，进一步深入评估Agmb-447在更大规模患者群体中的疗效与安全性。随着2期研究的即将铺开，业内目光已聚焦于Agomab能否延续其研发势能，以及Inspiria研究最终能收获怎样的临床答卷。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186837702","title":"Agomab公布Ontunisertib治疗纤维狭窄型克罗恩病的新时代2B期研究设计方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1186837702","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186837702?lang=zh_cn&edition=full","pubTime":"2026-06-24 04:06","pubTimestamp":1782245174,"startTime":"0","endTime":"0","summary":"AgomAb Therapeutics公司宣布，已为其候选药物Ontunisertib针对纤维狭窄型克罗恩病的治疗，完成了名为“Nov-Era”的2B期临床研究方案设计。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agomab.com","stockEarnings":[{"period":"1week","weight":0.0607},{"period":"1month","weight":-0.393},{"period":"3month","weight":-0.3058},{"period":"6month","weight":-0.1385},{"period":"1year","weight":-0.4325},{"period":"ytd","weight":-0.4325}],"compareEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":0.0212},{"period":"3month","weight":0.0313},{"period":"6month","weight":0.1459},{"period":"1year","weight":0.16},{"period":"ytd","weight":0.1417}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"AgomAb Therapeutics NV最初于2017年4月13日根据比利时法律注册成立为比利时私人有限责任公司，并于2019年3月14日转换为比利时有限责任公司。该公司是一家临床阶段的生物制药公司，专注于为存在高度未满足医疗需求的纤维炎症性疾病开发新型疾病修饰疗法。","exchange":"NASDAQ","name":"AgomAb Therapeutics","nameEN":"AgomAb Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AgomAb Therapeutics(AGMB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供AgomAb Therapeutics(AGMB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"AgomAb Therapeutics,AGMB,AgomAb Therapeutics股票,AgomAb Therapeutics股票老虎,AgomAb Therapeutics股票老虎国际,AgomAb Therapeutics行情,AgomAb Therapeutics股票行情,AgomAb Therapeutics股价,AgomAb Therapeutics股市,AgomAb Therapeutics股票价格,AgomAb Therapeutics股票交易,AgomAb Therapeutics股票购买,AgomAb Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AgomAb Therapeutics(AGMB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供AgomAb Therapeutics(AGMB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}